Cargando…
Antitumoral RNA‐targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies
Oligonucleotide therapeutics, drugs consisting of 10–50 nucleotide‐long single‐ or double‐stranded DNA or RNA molecules that can bind to specific DNA or RNA sequences or proteins, include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), aptamers, and decoys. Th...
Autores principales: | Taniguchi, Hiroaki, Suzuki, Yasunori, Imai, Kohzoh, Adachi, Yasushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459246/ https://www.ncbi.nlm.nih.gov/pubmed/35701833 http://dx.doi.org/10.1111/cas.15461 |
Ejemplares similares
-
Therapeutic siRNA targeting the cancer cell stemness regulator PRDI-BF1 and RIZ domain zinc finger protein 14
por: IMAI, Kohzoh, et al.
Publicado: (2022) -
Cancer stem cells in human gastrointestinal cancer
por: Taniguchi, Hiroaki, et al.
Publicado: (2016) -
PRDM14 is overexpressed in chronic pancreatitis prior to pancreatic cancer
por: Moriya, Chiharu, et al.
Publicado: (2018) -
Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
por: Li, Shasha, et al.
Publicado: (2021) -
A Human/Mouse Chimeric Monoclonal Antibody against Intercellular Adhesion Molecule‐1 for Tumor Radioimmunoimaging
por: Yamamura, Miyuki, et al.
Publicado: (1996)